BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Breckenridge Pharmaceutical, Inc. Announces Approval of Rizatriptan Benzoate ODT (Orally Disintegrating Tablets)


7/3/2013 10:50:59 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

BOCA RATON, Fla., July 3, 2013 /PRNewswire/ -- Breckenridge Pharmaceutical, Inc. announces the immediate launch of Rizatriptan Benzoate Orally Disintegrating Tablets. The U.S. Food and Drug Administration granted finalapproval for the Abbreviated New Drug Application (ANDA) for this product on July 1, 2013, approximately nine (9) months prior to expiration of the pediatric-exclusivity period for the challenged Orange Book patent (April 1, 2014). Breckenridge's ANDA to Maxalt-MLT® contained a Paragraph IV certification patent challenge, permitting launch after the 180-day exclusivity period of the first filer.

Breckenridge's Rizatriptan Benzoate ODT is manufactured and supplied by Natco Pharma Limited, the ANDA holder, and will be supplied in both 5mg and 10mg strengths. Rizatriptan Benzoate Orally Disintegrating Tablets are AB rated to Maxalt-MLT®, a $200 million dollar brand drug marketed by Merck & Co., Inc. Maxalt-MLT® is a prescription medicine indicated for the acute treatment of migraines. Breckenridge and Natco also launched Rizatriptan Benzoate Tablets on December 31, 2012.

Breckenridge's patent challenge regarding Rizatriptan Benzoate Orally Disintegrating Tablets is a continuing part of its larger aggressive Paragraph IV strategy commenced a few years ago. Since the beginning of 2011, Breckenridge has filed twelve (12) Paragraph IV patent challenges and intends to continue that trend in the next several years, focusing on niche Paragraph IV opportunities with certain barriers to entry.

About Breckenridge:

Breckenridge is a privately-held pharmaceutical marketing, research and development company founded in 1983 that markets a broad range of generic prescription products and Medical Foods in many therapeutic categories. The Breckenridge label is recognized by Wholesalers, Distributors, Chains, and Managed Care Accounts, as well as Retail Pharmacies nationwide. The company markets over 60 products in a variety of dosage forms including: Tablets, Capsules, Soft Gel Capsules, and Liquids, and Powders.

SOURCE Breckenridge Pharmaceutical, Inc.



Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES